One in Ten Americans Now Takes GLP-1 Drugs for Weight Loss as Obesity Rate Drops

GLP-1 Medication Use Surges Among American Adults

The percentage of U.S. adults who currently take GLP-1 medications for weight loss purposes has risen to 11% in 2026, up significantly from 3% in 2024. Meanwhile, 15% report having used the medicine for weight loss at some point, representing an increase of nine percentage points. The dramatic surge signals a fundamental transformation in how Americans approach weight management, moving pharmaceutical solutions from niche treatments into mainstream healthcare. A massive 91% of Americans now recognize GLP-1 drugs intended for weight loss purposes, up from 80% awareness in 2024.

The findings come from the Gallup National Health and Well-Being Index, which conducted a web survey of 5,065 U.S. adults from May 28 to June 5, 2026. Researchers used the probability-based Gallup Panel encompassing all 50 states and the District of Columbia to ensure representative results. The survey first asked respondents whether they have ever taken weight loss medications such as semaglutide (brand names Ozempic and Wegovy), liraglutide (brand name Saxenda) or tirzepatide (brand names Mounjaro and Zepbound). Those who answered yes then faced a follow-up question about current usage of these same medications.

FDA Approvals Sparked Mainstream Adoption

The Food and Drug Administration approved the Novo Nordisk drug Wegovy (semaglutide) for weight loss in 2021. Since that time, other options have come on the market, expanding consumer choices and driving widespread adoption. The Eli Lilly drug Zepbound (tirzepatide) received FDA approval in November 2023, providing Americans with additional pharmaceutical options for managing their weight. These regulatory milestones transformed medications originally developed for type 2 diabetes into powerful tools for weight management that doctors now prescribe to millions of patients.

GLP-1 receptor agonists were originally developed to help people with type 2 diabetes regulate blood sugar levels. Researchers soon noticed another effect: patients lost significant amounts of weight because the drugs slow stomach emptying, reduce appetite and increase feelings of fullness. That discovery prompted pharmaceutical companies to pursue additional FDA approvals specifically for weight loss indications, creating an entirely new category of obesity treatment medications. The drugs work by mimicking a hormone that targets areas of the brain involved in regulating appetite and food intake.

National Obesity Rate Shows Meaningful Decline

After peaking at a record high of 39.9% in 2022, the U.S. adult obesity rate has gradually dropped to 36.4% thus far in 2026. Gallup describes this as a statistically meaningful decline that continues to inversely track with increased usage of GLP-1 medicine nationally. The correlation suggests these medications may be contributing to measurable improvements in public health outcomes at a population level. Gallup calculates obesity using the federal standard of having a BMI of 30 or higher, based on self-reported height and weight data from survey respondents across all demographics.

The percentage of Americans who have been diagnosed with diabetes-a lifetime disease that doctors can manage but not cure-has remained steady since 2023 after 15 years of slowly rising rates that occurred alongside rising obesity. A declining obesity rate would naturally stabilize, but not reduce, the percentage of adults who have already received a diabetes diagnosis. The 2026 obesity results draw from 10,091 respondents from surveys conducted February 18 to March 3 and May surveys, providing robust sample sizes for statistical analysis.

Historical Context Reveals Dramatic Obesity Increases

It wasn’t that long ago that a much smaller percentage of Americans faced obesity classification. A decade ago in 2016, just 28.4% of Americans were obese, according to Gallup tracking data. In 2008, the rate stood at only 25.5%, illustrating how rapidly obesity prevalence climbed over the past two decades. The recent downturn marks the first sustained reversal of this troubling public health trend, offering hope that pharmaceutical interventions may help turn the tide on America’s obesity epidemic when combined with lifestyle modifications and preventive care.

Health experts increasingly view the survey data as evidence of a tipping point for pharmaceutical weight management. More than one in ten Americans now use these medications, moving GLP-1 drugs beyond celebrity headlines into everyday medical practice. The findings show that obesity treatment and societal views on weight management shift toward pharmaceutical intervention rather than solely lifestyle issues. This transformation reflects both improved drug efficacy and growing acceptance that obesity represents a complex medical condition requiring comprehensive treatment approaches that may include medication.

Side Effects Remain a Consideration

GLP-1 drugs have helped many people lose weight, but they don’t work perfectly for everyone. These medications can cause side effects in some people, including severe nausea and negative impacts on smell or taste. Patients considering these treatments must weigh potential benefits against possible adverse reactions, working closely with healthcare providers to monitor their response. The most common side effects typically involve the gastrointestinal system, as these drugs fundamentally alter how the stomach processes food and signals fullness to the brain.

As drug companies develop more palatable delivery methods, more Americans will likely embrace GLP-1 treatments. The drugs typically require regular injections, but researchers work on alternative formulations including oral medications that could improve patient compliance. Pharmaceutical companies invest heavily in next-generation GLP-1 medications that may offer improved efficacy with fewer side effects, potentially expanding the pool of patients who can benefit from these therapies. The rapid evolution of this drug class suggests the 11% current usage rate may climb even higher in coming years as new options reach the market.